Sorbitan trioleate
Based on 1 Customer Validation
Sorbitan trioleate (Span 85) is an orally active non-ionic surface active agent. Sorbitan trioleate can be used as an excipient, such as surfactant, emulsifier, lubricant, wetting agent, dispersant, thickener, defoamer.
For research use only. We do not sell to patients.
- CAS No.: 26266-58-0
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Pharmaceutical excipients, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs[1][2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (5-week-old)[2]
-
Dosage:12.5; 50.0; 200.0 mg/kg
-
Administration:i.v.; daily; 35 days
-
Result:Showed no abnormalities in general symptoms, body weight gain, or food/water consumption compared to controls at all doses.
Observed only a significant decrease in Na and Cl levels in males at 12.5 mg/kg.
Found any statistically significant changes in hematological, serum biochemical, or organ weight parameters fell within normal ranges at 12.5 mg/kg and 50.0 mg/kg.
Showed no meaningful gross or histological tissue changes beyond minor, non-toxic effects at 12.5 mg/kg and 50.0 mg/kg.
Induced significant decreases in red blood cell count, hemoglobin, and hematocrit, alongside significant increases in prothrombin time and reticulocyte count, indicating mild anemia at 200.0 mg/kg.
Caused significant increase in total cholesterol; significant decreases in male alkaline phosphatase, blood urea nitrogen, albumin, A/G ratio, sodium, chloride, and creatinine; significant decreases in female glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, albumin, A/G ratio, sodium, chloride, and creatinine at 200.0 mg/kg.
Chemical Information
-
CAS No. 26266-58-0
-
Appearance Liquid (Density: 0.94 g/cm3)
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OC[C@@H](O)[C@@H]1[C@H](OC(CCCCCCC/C=C\CCCCCCCC)=O)[C@@H](OC(CCCCCCC/C=C\CCCCCCCC)=O)CO1)=O
-
Synonyms
Span 85
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 200 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sonwai S, et al. Crystallization kinetics of cocoa butter in the presence of sorbitan esters. Food Chem. 2017;214:497-506. [Content Brief]
[2]. Yamamoto H, et al. Study on subacute toxicity of intravenous sorbitan trioleate (STO) in Wistar rats. J Toxicol Sci. 1983;8(4):301-310. [Content Brief]
[3]. Lanigan RS, et al. Final report on the safety assessment of sorbitan caprylate, sorbitan cocoate, sorbitan diisostearate, sorbitan dioleate, sorbitan distearate, sorbitan isostearate, sorbitan olivate, sorbitan sesquiisostearate, sorbitan sesquistearate, and sorbitan triisostearate. Int J Toxicol. 2002;21 Suppl 1:93-112. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz